Market Place
Dublin, Ireland - date 19 February 2018 – APC, a process development, design and innovation company, today announced the appointment of David Downey and Eoin McManus to its executive team.
These appointments reflect the significant and ongoing growth of APC’s business, with a doubling of headcount to 120 in the last two years.
Mr. Downey was most recently with Almac Group, as Vice President Commercial Operations, within the Drug Product business unit and brings more than twenty years of experience in business development, marketing and client management with a proven track record of building and developing successful outsource organisations.
Mr. McManus was most recently with Eli Lilly and Company, as Business Unit Leader, Kinsale Operations, leading its Engineering function, a company where he spent twenty-six years, with a proven track record in leading R&D, technical transfer, manufacturing and engineering organisations. He has championed the implementation of novel technologies such as continuous processing within the company.
Based at APC headquarters in Dublin, Ireland, Mr Downey and Mr McManus will report to Dr Mark Barrett, APC’s Chief Executive Officer.
Mr. Barrett states “we are delighted to welcome David and Eoin to APC during this very exciting period in our company history. Both are excellent additions to our management team and join at a time when we are seeing unprecedented demand for our innovative capabilities and services accelerating breakthrough innovations in cell therapies, personalised oncology therapies and viral vector technologies for many of our client partners. I look forward to David’s leadership of our commercial teams, meeting the increased needs of our clients along with recognising and communicating APC’s unique value proposition to the market. In parallel, Eoin will lead our Technical and Operational teams providing a unique environment for best in class scientific output that can materially benefit our client partners and the patients they serve. As a company our key purpose is to accelerate, through state of the art science and engineering, the development and launch of new medicines through state of the art science and engineering. With these latest appointments we are now well placed to deliver upon this global ambition”.
Mr. Downey started his career in Quality Assurance for Scherer DDS (now part of Catalent) in 1994 before moving to Quintiles Limited as Packaging Manager, then Director of Project Management, for their Clinical Trial packaging services. Following that Mr. Downey relocated to Italy in 2002 working for Patheon Italia as Business Manager, for their Monza Operations. Over the following five years he progressed to European Director of Business Management managing the client interface and commercial Technology Transfer teams. Mr. Downey then joined Almac Group in 2008.
Mr. McManus started his career in Engineering for Eli Lilly in 1991 before progressing to Operations in 1998 as Team Leader managing two new production areas. In 2004, he led Maintenance and then Process Engineering organisations with a focus on new technologies and technical transfers. Following that in 2011, Mr. McManus relocated to the USA to lead a late stage R&D group having been promoted to Director for Technology Design and Development within Chemical Process R&D team at Eli Lilly. In 2013, he returned to Ireland as Business Unit Leader – Small Molecule Operations before moving to lead the Engineering function in 2017.
About
APC
Accelerating the development of quality life-changing medicines to patients, APC utilises its state-of-the-art technology platforms (ACHIEVETM and BioACHIEVETM) across chemical and biological molecules to reduce time, cost and risk for your product. Headquartered in Dublin and partnering with 8 of the top-10 global pharmaceutical, and 5 of the top-10 biotechnology companies, APC provides its services globally. Employing the best and brightest in the fields of Chemical and Process Engineering APC design, develop and optimise your manufacture processes. APC combines technologies ranging from Process Modelling, automated lab reactors and Process Analytical Technology with in-house developed capabilities in continuous processing, process control and advanced analytics to empower the development of synthetic and biologic medicines.
For more information visit www.approcess.com or e-mail innovate@approcess.com
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : APC by APPROCESS is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
